title: United States experience and perspectives with trazodone.
abstract: In the United States, trazodone has shown efficacy comparable with tricyclic antidepressants. Trazodone's side-effect profile, however, is vastly superior to the older drugs. In cases of overdose, trazodone alone has not caused a single death. For depressed patients, starting with 150 mg/day of trazodone, preferably at night, produces best results. Preliminary data suggest good safety and efficacy for patients with chronic depression when used up to 5 1/2 years. New uses for trazodone include treatment of insomnia, chronic pain, obsessive-compulsive disorder (OCD), bulimia nervosa, and psychogeriatrics.
authors.affiliation: Fabre Clinic, Houston, Texas 77004.
authors.forename: L F
authors.initials: LF
authors.lastname: Fabre
mesh_terms: D000368:Aged; D002032:Bulimia / Q000188:drug therapy; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D014196:Trazodone / Q000627:therapeutic use*; D014481:United States
chemical_list: D014196:Trazodone